IDEXX Laboratories, Inc. (IDXX)
IDXX Stock Price Chart
Explore IDEXX Laboratories, Inc. interactive price chart. Choose custom timeframes to analyze IDXX price movements and trends.
IDXX Company Profile
Discover essential business fundamentals and corporate details for IDEXX Laboratories, Inc. (IDXX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
21 Jun 1991
Employees
11.00k
Website
https://www.idexx.comCEO
Jonathan J. Mazelsky
Description
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services. In the livestock, poultry, and dairy markets, IDEXX supplies diagnostic and health-monitoring solutions. Its water testing portfolio includes products designed to detect various microbiological contaminants, notably the Colilert, Colilert-18, and Colisure tests for total coliforms and E. coli, as well as Enterolert, Pseudalert, Filta-Max, Filta-Max xpress, Legiolert, and Quanti-Tray products. Beyond these, IDEXX extends its reach to human point-of-care medical diagnostics, offering electrolyte and blood gas analyzers, and SARS-CoV-2 RT-PCR tests. Other key offerings encompass in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers, as well as SNAP rapid assay test kits. Veterinary software and services for both independent clinics and large corporate veterinary groups are also part of its offerings. The company distributes its extensive product and service catalog through its own dedicated marketing, customer service, sales, and technical service teams, supplemented by independent distributors and other resellers. IDEXX Laboratories, Inc. was established in 1983 and maintains its headquarters in Westbrook, Maine.
IDXX Financial Timeline
Browse a chronological timeline of IDEXX Laboratories, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is $3.95, while revenue estimate is $1.20bn.
Earnings released on 5 May 2026
EPS came in at $3.47 surpassing the estimated $3.41 by +1.76%, while revenue for the quarter reached $1.14bn , beating expectations by +2.00%.
Earnings released on 2 Feb 2026
EPS came in at $3.08 surpassing the estimated $2.93 by +5.12%, while revenue for the quarter reached $1.09bn , beating expectations by +1.67%.
Earnings released on 3 Nov 2025
EPS came in at $3.40 surpassing the estimated $3.14 by +8.28%, while revenue for the quarter reached $1.11bn , beating expectations by +2.98%.
Earnings released on 4 Aug 2025
EPS came in at $3.63 surpassing the estimated $3.28 by +10.67%, while revenue for the quarter reached $1.11bn , beating expectations by +4.43%.
Earnings released on 1 May 2025
EPS came in at $2.96 surpassing the estimated $2.85 by +3.86%, while revenue for the quarter reached $998.43m , beating expectations by +0.13%.
Earnings released on 3 Feb 2025
EPS came in at $2.62 surpassing the estimated $2.39 by +9.62%, while revenue for the quarter reached $954.29m , beating expectations by +2.05%.
Earnings released on 31 Oct 2024
EPS came in at $2.80 surpassing the estimated $2.68 by +4.48%, while revenue for the quarter reached $975.54m , missing expectations by -0.49%.
Earnings released on 6 Aug 2024
EPS came in at $3.02 surpassing the estimated $2.88 by +4.86%, while revenue for the quarter reached $1.00bn , missing expectations by -0.31%.
Earnings released on 1 May 2024
EPS came in at $2.81 surpassing the estimated $2.67 by +5.24%, while revenue for the quarter reached $964.10m , missing expectations by -0.03%.
Earnings released on 5 Feb 2024
EPS came in at $2.32 surpassing the estimated $2.12 by +9.43%, while revenue for the quarter reached $901.60m , beating expectations by +1.16%.
Earnings released on 1 Nov 2023
EPS came in at $2.53 surpassing the estimated $2.37 by +6.75%, while revenue for the quarter reached $915.53m , missing expectations by -1.21%.
Earnings released on 1 Aug 2023
EPS came in at $2.67 surpassing the estimated $2.47 by +8.10%, while revenue for the quarter reached $943.63m , beating expectations by +0.99%.
Earnings released on 2 May 2023
EPS came in at $2.55 surpassing the estimated $2.42 by +5.37%, while revenue for the quarter reached $900.20m , beating expectations by +0.87%.
Earnings released on 6 Feb 2023
EPS came in at $2.05 surpassing the estimated $1.94 by +5.67%, while revenue for the quarter reached $828.57m , beating expectations by +0.93%.
Earnings released on 1 Nov 2022
EPS came in at $2.15 surpassing the estimated $2.04 by +5.39%, while revenue for the quarter reached $841.66m , beating expectations by +1.40%.
Earnings released on 2 Aug 2022
EPS came in at $1.56 matching the estimated $1.56, while revenue for the quarter reached $860.55m , missing expectations by -0.30%.
Earnings released on 4 May 2022
EPS came in at $2.27 surpassing the estimated $2.26 by +0.44%, while revenue for the quarter reached $836.55m , missing expectations by -0.07%.
Earnings released on 2 Feb 2022
EPS came in at $1.89 surpassing the estimated $1.71 by +10.53%, while revenue for the quarter reached $801.09m , beating expectations by +2.46%.
Earnings released on 2 Nov 2021
EPS came in at $2.03 surpassing the estimated $1.91 by +6.28%, while revenue for the quarter reached $810.42m , beating expectations by +1.67%.
Earnings released on 30 Jul 2021
EPS came in at $2.34 surpassing the estimated $2.02 by +15.84%, while revenue for the quarter reached $826.14m , beating expectations by +5.06%.
IDXX Stock Performance
Access detailed IDXX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
